Anti-Rat Kappa Light Chain – Purified in vivo GOLD™ Functional Grade

Pricing & Details

Product No.I-2027
MAR 18.5
Kappa Light Chain
Formats AvailableView All
Product Type
Monoclonal Antibody
Mouse IgG2a k
Prod No.
Add to cart
1.0 mg
In stock
Min: 1
Step: 1
5.0 mg
In stock
Min: 1
Step: 1
25 mg
In stock
Min: 1
Step: 1
50 mg
In stock
Min: 1
Step: 1
100 mg
In stock
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Host Species
Soluble rat immunoglobulin
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
≥95% by SDS Page
≥95% monomer by analytical SEC
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


MAR 18.5 activity is directed against rat kappa immunoglobulin light chain of both RI-1a and RI-1b allotypes.
Antigen Distribution
Immunoglobulins consist of heavy chains and light chains. Kappa is a class of light chain and is encoded by the V (variable), J (joining), and C (constant) segments.
MAR 18.5 is a monoclonal antibody directed against rat kappa light chains1. MAR 18.5 was generated by immunizing SJL/J mice with soluble rat immunoglobulin, followed by the creation of a B cell hybridoma line via fusion of immune spleen with P3X63Ag8 myeloma cells. MAR 18.5 hybridoma cells secrete an IgG2a kappa monoclonal antibody that strongly binds to protein A. Additionally, MAR 18.5 antibody binds similarly to Ig of RI-1a and RI-1b allotypes. MAR 18.5 antibody can be used in combination with anti-CD19 and anti-CD22 for in vivo B cell depletion in mice2,3. In a study on Fcγ receptor-mediated phagocytosis, MAR 18.5 antibody was used as a secondary cross-linking antibody during stimulation of macrophages grown in medium lacking L cell–conditioned medium (LCM) and treated with chilled supernatant from the rat anti-FcγR 2.4G2 hybridoma4. Additionally, MAR 18.5 antibody has been used for T cell isolation and complement lysis in combination with J11d.2 (anti-heat-stable Ag), 2.43 (anti-CD8), M5/114 (anti-class II), and 2.4G2 (anti-FcR)5.

Antigen Details

References & Citations

1. Lanier LL, Gutman GA, Lewis DE, et al. Hybridoma. 1(2):125-131. 1982.
2. Säwén P, Lang S, Mandal P, et al. Cell Rep.;14(12):2809-2818. 2016.
3. Keren Z, Naor S, Nussbaum S, et al. Blood. 117(11):3104-3112. 2011.
4. Fitzer-Attas CJ, Lowry M, Crowley MT, et al. J Exp Med. 191(4):669-682. 2000.
5. Hurst SD, Sitterding SM, Ji S, Barrett TA. Proc Natl Acad Sci U S A. 94(8):3920-3925. 1997.
6. Nilsson G, Matsson P, Ahlstedt S. Scand J Immunol. 31(1):53-57. 1990.
7. Elbe-Bürger A, Mommaas AM, Prieschl EE, et al. Immunology. 101(2):242-253. 2000.
8. Zheng Y, Zhou ZZ, Lyttle CR, et al. J Leukoc Biol. 44(1):27-32. 1988.
9. Zhou ZZ, Zheng Y, Steenstra R, et al. Autoimmunity. 3(2):125-134. 1989.
10. Jonsson CA, Carlsten H. Int Immunopharmacol. 3(1):31-37. 2003.
11. Mpandi M, Otten LA, Lavanchy C, et al. J Virol. 77(17):9369-9377. 2003.
12. Reitan SK, Hannestad K. Proc Natl Acad Sci U S A. 99(11):7588-7593. 2002.
Elisa Sandwich Protocol
General Western Blot Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.